Navigation Links
Cephalon Granted Temporary Restraining Order in AMRIX® Patent Litigation
Date:5/20/2011

ments regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Contacts:

Media:
Fritz Bittenbender
610-883-5855 (office)

610-457-7041 (cell)
fbittenb@cephalon.com

Natalie de Vane
610-727-6536 (office)
610-999-8756 (cell)
ndevane@cephalon.com

Investor Relations:
Chip Merritt
610-738-6376 (office)
cmerritt@cephalon.com

Joseph Marczely
610-883-5894 (office)
jmarczely@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Files Definitive Consent Revocation Statement, Commences Mailing to Shareholders
2. Cephalon Recommends Shareholders Reject Valeant Nominees
3. Cephalon First Quarter 2011 Earnings Conference Call Tuesday, May 3, 2011 at 5:00 p.m. EDT
4. Cephalon Announces Positive Topline Results From a Phase IV Study of NUVIGIL in Shift Work Disorder
5. Cephalon to Hold Public Memorial Service to Celebrate the Life of Company Founder, Frank Baldino, Jr., Ph.D.
6. Cephalon Mourns the Passing of Founder, Chairman and CEO, Frank Baldino Jr., Ph.D.
7. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
8. Cephalon Reports Record Earnings and Raises 2010 Guidance
9. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
10. Cephalon Announces Chairman and CEO to Take Medical Leave of Absence
11. Cephalon Completes Acquisition of Arana Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... (PRWEB) October 18, 2014 The ... - Trends and Forecasts to 2019", analyzes the ... in order to understand the industry details such ... opportunities across various geographic regions. , Browse 81 ... 202 Slides and in-depth TOC on “1,6-Hexanediol Market ...
(Date:10/18/2014)... October 18, 2014 The Asian Electronic Medical ... in Asian with analysis and forecast of revenue. The electronic ... grow to $2,328.0 million by 2018, at a CAGR of ... of the Asian Electronic Medical Record (EMR) market, to get ... a glimpse of the segmentation of the market in the ...
(Date:10/18/2014)... 18, 2014 The “Global Diagnostic ... Monitor), by End-user (Hospitals, Home/Ambulatory, Research Center, Physician ... 12) -Global Forecast to 2020” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
(Date:10/17/2014)... For the seventh consecutive year, ... in today’s print issue of Science magazine. , ... Survey polled employees in the biotechnology, pharmaceutical and ... Rankings were determined based on responses from ... companies on 23 characteristics, including financial strength, leadership ...
Breaking Biology Technology:1,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 21,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 31,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 41,6-Hexanediol Market Projected to Reach $916.1 Million at a CAGR of 8.3% by 2019 – Report by MarketsandMarkets 5The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 2The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 3The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 4The Electrocardiograph (ECG) Market Is Expected to Reach $5,435 Million By 2020 - New Research Report by MarketsandMarkets 5DuPont Named Top Employer by Science Magazine 2DuPont Named Top Employer by Science Magazine 3
... 2 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ) ... Healthcare Conference on Monday, January 7, at 11:30 ... webcast of the,presentation at:, http://www.metameetings.com/webcasts/jpmorgan/healthcare08 , ... 15 minutes early in order to,register and download ...
... CARLOS, Calif., Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ... corporate presentation at the upcoming JPMorgan 26th Annual Healthcare,Conference ... California on,Tuesday, January 8, 2008, at 4:30 p.m. Pacific ... live audio and slideshow,webcast through a link posted on ...
... PRINCETON, N.J., Dec. 31 Pharmasset, Inc.,(Nasdaq: ... to,discovering, developing and commercializing novel drugs to treat ... year ended,September 30, 2007. Pharmasset reported a net ... $0.46 per share, as compared to a net ...
Cached Biology Technology:Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
(Date:10/15/2014)... from strains of influenza virus increases with the latest ... complacent that the most substantial threats have been identified, ... arise when a new virus strain – against which ... in the human population. There have been five such ... which – the 1918 Spanish Flu – cost 50 ...
(Date:10/15/2014)... bacterial pneumonia in female mice to an enzyme activated ... naturally more resistant to respiratory infections than males. Now, ... resistance to bacterial pneumonia in female mice is linked ... also show that this enzyme is ultimately activated by ... The team, lead by Professor Lester Kobzik at the ...
(Date:10/14/2014)... cancer tumors scavenge and hoard copper that is an ... be a fatal weakness. , Researchers at Duke ... cells by delivering a trove of copper along with ... with the mineral, leaving non-cancer cells healthy. , The ... for other uses, could soon be tested in clinical ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... as the insects and plants in the network are ... question is difficult to answer because there is no ... or insects first appeared and almost none follow both ... Knight and her then postdoctoral research associate Laura Burkle ...
... on the challenge of providing the first insights into how ... with scientists from the John Innes Centre on a project ... Society and 2000 from the British Society for Plant Pathology., ... to Take-all, one of the most serious fungal diseases of ...
... everyone,s skin, yet one in five people is lucky enough ... In a boon for teenagers everywhere, a UCLA study conducted ... Los Angeles Biomedical Research Institute has discovered that acne bacteria ... may protect the skin. The findings, published ...
Cached Biology News:Walking in the footsteps of 19th and 20th century naturalists 2Walking in the footsteps of 19th and 20th century naturalists 3Walking in the footsteps of 19th and 20th century naturalists 4Walking in the footsteps of 19th and 20th century naturalists 5Growing talent -- schools to provide vital knowledge for food security 2New study could explain why some people get zits and others don't 2New study could explain why some people get zits and others don't 3
... timer, SB3, Fully adjustable mixing angle, Variable ... to hold a number of different sized ... for aerating cultures, keeping biological samples in ... rotator can be used in incubators up ...
...
Fingerprinting II database sharing tools is an optional module for the Fingerprinting II Basic software package that enables peer-to-peer data exchange over the internet and provides external databas...
Fingerprinting II cluster analysis is an optional module that adds dendrogram and phylogenetic tree construction, cluster and group significance, and congruence of techniques functions to the Fingerp...
Biology Products: